Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 73, Issue 5

The laboratory investigation, management, and infection prevention and control of : a narrative review to inform the 2024 national guidance update in England Open Access

This article is part of the Candida collection.

Abstract

The emergent fungal pathogen is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for . This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of . A multidisciplinary response is needed to control transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.

  • Received:
  • Accepted:
  • Published Online:
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001820
2024-05-21
2025-05-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/73/5/jmm001820.html?itemId=/content/journal/jmm/10.1099/jmm.0.001820&mimeType=html&fmt=ahah

References

  1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53:41–44 [View Article] [PubMed]
     [Google Scholar]
  2. Kim M-N, Shin JH, Sung H, Lee K, Kim E-C et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis 2009; 48:e57–e61 [View Article] [PubMed]
     [Google Scholar]
  3. Keighley C, Garnham K, Harch SAJ, Robertson M, Chaw K et al. Candida auris: diagnostic challenges and emerging opportunities for the clinical microbiology laboratory. Curr Fungal Infect Rep 2021; 15:116–126 [View Article] [PubMed]
     [Google Scholar]
  4. Fisher MC, Denning DW. The WHO fungal priority pathogens list as a game-changer. Nat Rev Microbiol 2023; 21:211–212 [View Article] [PubMed]
     [Google Scholar]
  5. Khatamzas E, Madder H, Jeffery K. Neurosurgical device-associated infections due to Candida auris - three cases from a single tertiary center. J Infect 2019; 78:409–421 [View Article] [PubMed]
     [Google Scholar]
  6. Ahmad S, Alfouzan W. Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms 2021; 9:807 [View Article] [PubMed]
     [Google Scholar]
  7. Tanne JH. Candida auris: CDC warns of risk of new, drug resistant strain in US. BMJ 2021; 374:1880 [View Article]
     [Google Scholar]
  8. Yadav A, Singh A, Wang Y, Haren MHV, Singh A et al. Colonisation and transmission dynamics of Candida auris among chronic respiratory diseases patients hospitalised in a chest hospital. J Fungi 2021; 7: [View Article]
     [Google Scholar]
  9. Chybowska AD, Childers DS, Farrer RA. Nine things genomics can tell us about Candida auris. Front Genet 2020; 11:351 [View Article]
     [Google Scholar]
  10. Chayaporn S, Karrie Kwan Ki K, Kar Mun L, Mei Gie T, Patipan B et al. Discovery of the sixth Candida auris clade in Singapore. medRxiv 2023; 2023:
     [Google Scholar]
  11. Price TK, Mirasol R, Ward KW, Dayo AJ, Hilt EE et al. Genomic characterizations of Clade III lineage of Candida auris, California, USA. Emerg Infect Dis 2021; 27:1223–1227 [View Article] [PubMed]
     [Google Scholar]
  12. Lyman M, Forsberg K, Reuben J, Dang T, Free R et al. Notes from the field: transmission of pan-resistant and echinocandin-resistant Candida auris in health care facilities - Texas and the District of Columbia, January-April 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1022–1023 [View Article] [PubMed]
     [Google Scholar]
  13. Kohlenberg A, Monnet DL, Plachouras D. Candida auris survey collaborative groupCandida auris survey collaborative group includes the following national experts Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro Surveill 2022; 27:2200846 [View Article] [PubMed]
     [Google Scholar]
  14. Nelson R. Emergence of resistant Candida auris. Lancet Microbe 2023; 4:e396 [View Article] [PubMed]
     [Google Scholar]
  15. van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H et al. Epidemiologic shift in Candidemia driven by Candida auris, South Africa. Emerg Infect Dis 2019; 25:1698–1707 [View Article]
     [Google Scholar]
  16. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41:285–295 [View Article] [PubMed]
     [Google Scholar]
  17. Driemeyer C, Falci DR, Oladele RO, Bongomin F, Ocansey BK et al. The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe 2022; 3:e464–e470 [View Article] [PubMed]
     [Google Scholar]
  18. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM et al. Candida auris: a review of the literature. Clin Microbiol Rev 2018; 31:e00029-17 [View Article] [PubMed]
     [Google Scholar]
  19. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 2011; 49:3139–3142 [View Article] [PubMed]
     [Google Scholar]
  20. Oh BJ, Shin JH, Kim M-N, Sung H, Lee K et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol 2011; 49:98–102 [View Article] [PubMed]
     [Google Scholar]
  21. Desnos-Ollivier M, Fekkar A, Bretagne S. Earliest case of Candida auris infection imported in 2007 in Europe from India prior to the 2009 description in Japan. J Mycol Med 2021; 31:101139 [View Article] [PubMed]
     [Google Scholar]
  22. Lamoth F, Kontoyiannis DP. The Candida auris alert: facts and perspectives. J Infect Dis 2018; 217:516–520 [View Article] [PubMed]
     [Google Scholar]
  23. Borman AM, Johnson EM. Candida auris in the UK: introduction, dissemination, and control. PLoS Pathog 2020; 16:e1008563 [View Article] [PubMed]
     [Google Scholar]
  24. Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 2013; 19:1670–1673 [View Article] [PubMed]
     [Google Scholar]
  25. CDC Tracking Candida auris: Centers for Disease Prevention and Control 2021. n.d https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html
  26. ECDC Rapid risk assessment: Candida auris in healthcare settings - Europe. Stockholm:European Centre for Disease Prevention and Control (ECDC); 2018 https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-healthcare-settings-europe accessed 23 April 2018
  27. Plachouras D, Lötsch F, Kohlenberg A, Monnet DL. Candida auris survey collaborative group Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019. Euro Surveill 2020; 25:2000240 [View Article] [PubMed]
     [Google Scholar]
  28. Mathur P, Hasan F, Singh PK, Malhotra R, Walia K et al. Five-year profile of candidaemia at an Indian trauma centre: high rates of Candida auris blood stream infections. Mycoses 2018; 61:674–680 [View Article] [PubMed]
     [Google Scholar]
  29. Sharp A, Muller-Pebody B, Charlett A, Patel B, Gorton R et al. Screening for Candida auris in patients admitted to eight intensive care units in England, 2017 to 2018. Euro Surveill 2021; 26:1900730 [View Article] [PubMed]
     [Google Scholar]
  30. Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol Open Access 2019; 57:1–12 [View Article]
     [Google Scholar]
  31. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017; 64:134–140 [View Article] [PubMed]
     [Google Scholar]
  32. Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM et al. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis 2019; 25:1780–1781 [View Article] [PubMed]
     [Google Scholar]
  33. Armaki MT, Omran SM, Jafarzadeh J, Tavakoli M, Kiakojuri K et al. First fluconazole-resistant Candida auris isolated from fungal Otitis in Iran. Curr Med Mycol 2021; 7:51–54
     [Google Scholar]
  34. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM et al. Candida auris: a review of the literature. Clin Microbiol Rev 2018; 31:e00029-17 [View Article] [PubMed]
     [Google Scholar]
  35. Hu S, Zhu F, Jiang W, Wang Y, Quan Y et al. Retrospective analysis of the clinical characteristics of Candida auris infection worldwide from 2009 to 2020. Front Microbiol 2021; 12:658329 [View Article] [PubMed]
     [Google Scholar]
  36. UKHSA Candida auris: laboratory investigation, management and infection prevention andcontrol: UK Health Security Agency; 2024 https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control
  37. Brown CS, Guy R. National public health response to Candida auris in England. J Fungi 2019; 5:93 [View Article] [PubMed]
     [Google Scholar]
  38. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med 2018; 379:1322–1331 [View Article] [PubMed]
     [Google Scholar]
  39. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 2016; 5:35 [View Article] [PubMed]
     [Google Scholar]
  40. Taori SK, Khonyongwa K, Hayden I, Athukorala GDA, Letters A et al. Candida auris outbreak: mortality, interventions and cost of sustaining control. J Infect 2019; 79:601–611 [View Article] [PubMed]
     [Google Scholar]
  41. Taori SK, Rhodes J, Khonyongwa K, Szendroi A, Smith M et al. First experience of implementing Candida auris real-time PCR for surveillance in the UK: detection of multiple introductions with two international clades and improved patient outcomes. J Hosp Infect 2022; 127:111–120 [View Article] [PubMed]
     [Google Scholar]
  42. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. J Infect 2021; 82:e45–e46 [View Article] [PubMed]
     [Google Scholar]
  43. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically Ill coronavirus disease patients, India, April-July 2020. Emerg Infect Dis 2020; 26:2694–2696 [View Article] [PubMed]
     [Google Scholar]
  44. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020; 81:266–275 [View Article] [PubMed]
     [Google Scholar]
  45. Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother 2017; 72:1794–1801 [View Article] [PubMed]
     [Google Scholar]
  46. Magnasco L, Mikulska M, Giacobbe DR, Taramasso L, Vena A et al. Spread of Carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically Ill patients: one step back in antimicrobial stewardship?. Microorganisms 2021; 9:95 [View Article] [PubMed]
     [Google Scholar]
  47. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA et al. Candida auris outbreak in a COVID-19 specialty care unit - Florida, July-August 2020. MMWR Morb Mortal Wkly Rep 2021; 70:56–57 [View Article] [PubMed]
     [Google Scholar]
  48. PAHO Epidemiological alert: Candida auris outbreaks in health care services in the contextof the COVID-19 pandemic: Pan American Health Organisation (PAHO); 2021 https://iris.paho.org/bitstream/handle/10665.2/53377/EpiUpdate6February2021_eng.pdf?sequence=1&isAllowed=y accessed 20 October 2021
  49. CDC Fungal diseases and COVID-19: Centers for Disease Prevention and Control; 2020 https://www.cdc.gov/fungal/covid-fungal.html
  50. Nobrega de Almeida J, Brandão IB, Francisco EC, de Almeida SLR, de Oliveira Dias P et al. Axillary digital thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil. Mycoses 2021; 64:1062–1072 [View Article] [PubMed]
     [Google Scholar]
  51. de Almeida JN, Francisco EC, Hagen F, Brandão IB, Pereira FM et al. Emergence of Candida auris in Brazil in a COVID-19 intensive care unit. J Fungi 2021; 7:220 [View Article] [PubMed]
     [Google Scholar]
  52. Villanueva-Lozano H, Treviño-Rangel R de J, González GM, Ramírez-Elizondo MT, Lara-Medrano R et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect 2021; 27:813–816 [View Article] [PubMed]
     [Google Scholar]
  53. Mulet Bayona JV, Tormo Palop N, Salvador García C, Fuster Escrivá B, Chanzá Aviñó M et al. Impact of the SARS-CoV-2 pandemic in Candidaemia, invasive aspergillosis and antifungal consumption in a tertiary hospital. J Fungi 2021; 7:440 [View Article] [PubMed]
     [Google Scholar]
  54. ECDC Rapid risk assessment: Candida auris outbreak in healthcare facilities in northern Italy, 2019-2021; 2022
  55. Allaw F, Kara Zahreddine N, Ibrahim A, Tannous J, Taleb H et al. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. Pathogens 2021; 10:157 [View Article] [PubMed]
     [Google Scholar]
  56. Senok A, Alfaresi M, Khansaheb H, Nassar R, Hachim M et al. Coinfections in patients hospitalized with COVID-19: a descriptive study from the United Arab Emirates. Infect Drug Resist 2021; 14:2289–2296 [View Article] [PubMed]
     [Google Scholar]
  57. Hanson BM, Dinh AQ, Tran TT, Arenas S, Pronty D et al. Candida auris Invasive Infections during a COVID-19 case surge. Antimicrob Agents Chemother 2021; 65:e0114621 [View Article] [PubMed]
     [Google Scholar]
  58. Codda G, Di Pilato V, Ball L, Giacobbe DR, Willison E et al. Molecular epidemiological investigation of a nosocomial cluster of C. Auris: evidence of recent emergence in Italy and ease of transmission during the COVID-19 pandemic. J Fungi 2021; 7:
     [Google Scholar]
  59. Goravey W, Ali GA, Ali M, Ibrahim EB, Al Maslamani M et al. Ominous combination: COVID-19 disease and Candida auris fungemia-case report and review of the literature. Clin Case Rep 2021; 9:e04827 [View Article] [PubMed]
     [Google Scholar]
  60. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D et al. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect 2017; 97:363–370 [View Article] [PubMed]
     [Google Scholar]
  61. Ruiz-Azcona L, Santibañez M, Roig FJ, Vanaclocha H, Ventero MP et al. Isolation of Candida auris in large hospitals in the autonomous community of Valencia; population-based study (2013-2017). Rev Iberoam Micol 2021; 38:141–144 [View Article] [PubMed]
     [Google Scholar]
  62. Briano F, Magnasco L, Sepulcri C, Dettori S, Dentone C et al. Candida auris Candidemia in critically ill, colonized patients: cumulative incidence and risk factors. Infect Dis Ther 2022; 11:1149–1160 [View Article] [PubMed]
     [Google Scholar]
  63. Kaur H, Wadhwa K, Jain K, Yadav A. Multidrug-resistant Candida auris: a global challenge. J Appl Biol Biotechnol 2021; 9:104–113
     [Google Scholar]
  64. Al-Rashdi A, Al-Maani A, Al-Wahaibi A, Alqayoudhi A, Al-Jardani A et al. Characteristics, risk factors, and survival analysis of Candida auris cases: results of one-year National Surveillance Data from Oman. J Fungi 2021; 7:31 [View Article] [PubMed]
     [Google Scholar]
  65. Shaukat A, Al Ansari N, Al Wali W, Karic E, El Madhoun I et al. Experience of treating Candida auris cases at a general hospital in the state of Qatar. IDCases 2021; 23:e01007 [View Article] [PubMed]
     [Google Scholar]
  66. Rossow J, Ostrowsky B, Adams E, Greenko J, McDonald R et al. Factors associated with Candida auris colonization and transmission in skilled nursing facilities with ventilator units, New York, 2016-2018. Clin Infect Dis 2021; 72:e753–e760 [View Article] [PubMed]
     [Google Scholar]
  67. Berrio I, Caceres DH, Coronell R W, Salcedo S, Mora L et al. Bloodstream infections with Candida auris among children in Colombia: clinical characteristics and outcomes of 34 cases. J Pediatric Infect Dis Soc 2021; 10:151–154 [View Article] [PubMed]
     [Google Scholar]
  68. Alvarado-Socarras JL, Vargas-Soler JA, Franco-Paredes C, Villegas-Lamus KC, Rojas-Torres JP et al. A cluster of neonatal infections caused by Candida auris at a large referral center in Colombia. J Pediatric Infect Dis Soc 2021; 10:549–555 [View Article] [PubMed]
     [Google Scholar]
  69. Mesini A, Saffioti C, Mariani M, Florio A, Medici C et al. First case of Candida auris colonization in a preterm, extremely low-birth-weight newborn after vaginal delivery. J Fungi 2021; 7:649 [View Article] [PubMed]
     [Google Scholar]
  70. Ramya GM, Balakrishnan U, Chandrasekaran A, Abiramalatha T, Amboiram P et al. Candida auris, an emerging pathogen - challenge in the survival of microprimies. Indian J Med Microbiol 2021; 39:367–369 [View Article] [PubMed]
     [Google Scholar]
  71. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2017; 13:e1006290 [View Article] [PubMed]
     [Google Scholar]
  72. Fasciana T, Cortegiani A, Ippolito M, Giarratano A, Di Quattro O et al. Candida auris: an overview of how to screen, detect, test and control this emerging pathogen. Antibiotics 2020; 9:1–14 [View Article] [PubMed]
     [Google Scholar]
  73. Lockhart SR, Lyman MM, Sexton DJ. Tools for detecting a “Superbug”: updates on Candida auris testing. J Clin Microbiol 2022; 60:e0080821 [View Article] [PubMed]
     [Google Scholar]
  74. Borman AM, Fraser M, Johnson EM. CHROMagarTM Candida Plus: a novel chromogenic agar that permits the rapid identification of Candida auris. Med Mycol Open Access 2021; 59:253–258 [View Article]
     [Google Scholar]
  75. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile Variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 2015; 53:1823–1830 [View Article] [PubMed]
     [Google Scholar]
  76. Mizusawa M, Miller H, Green R, Lee R, Durante M et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories?. J Clin Microbiol 2017; 55:638–640 [View Article] [PubMed]
     [Google Scholar]
  77. Mulet Bayona JV, Salvador García C, Tormo Palop N, Gimeno Cardona C. Candida for the detection of Candida auris in surveillance samples. Diagn Microbiol Infect Dis 2020; 98:115168 [View Article] [PubMed]
     [Google Scholar]
  78. Mulet Bayona JV, Salvador Garcia C, Tormo Palop N, Valentin Martin A, Gonzalez Padron C et al. Plus for detection of Candida auris and other Candida species from surveillance and environmental samples: a multicenter study. J Fungi 2022; 8:09
     [Google Scholar]
  79. Sasoni N, Maidana M, Latorre-Rapela MG, Morales-Lopez S, Berrio I et al. Candida auris and some Candida parapsilosis strains exhibit similar characteristics on CHROMagarTMCandida plus. Med Mycol 2022myac062 [View Article] [PubMed]
     [Google Scholar]
  80. White PL, Price JS, Cordey A, Backx M. Molecular diagnosis of yeast infections. Curr Fungal Infect Rep 2021; 15:67–80 [View Article] [PubMed]
     [Google Scholar]
  81. Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S et al. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genom 2015; 16:686 [View Article] [PubMed]
     [Google Scholar]
  82. Borman AM, Szekely A, Johnson EM. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med Mycol 2017; 55:563–567 [View Article] [PubMed]
     [Google Scholar]
  83. Bagal UR, Phan J, Welsh RM, Misas E, Wagner D et al. MycoSNP: a portable workflow for performing whole-genome sequencing analysis of Candida auris. Methods Mol Biol 2022; 2517:215–228 [View Article] [PubMed]
     [Google Scholar]
  84. Chow N, Parnell L, Escandon P, Govender N, Chiller T. S5.5a standing up FungiNet: genomic epidemiology and surveillance of fungal diseases. Med Mycol Open Access 2022; 60: [View Article]
     [Google Scholar]
  85. González-Durán E, Contreras-Pérez CU, Caceres DH, Ríos-Rosas C, Piñón-Ortega J de J et al. The use of readily available laboratory tests for the identification of the emerging yeast Candida auris in Mexico. Arch Microbiol 2022; 204:592 [View Article] [PubMed]
     [Google Scholar]
  86. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol 2017; 55:2996–3005 [View Article] [PubMed]
     [Google Scholar]
  87. WHO WHO model list of essential medicines - 23rd list, 2023: World Health Organisation; 2023 https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
  88. GAFFI GAFFI antifungal drug maps - micafungin: global action for fungal infections; 2023 https://drugsmaps.azurewebsites.net/maps/map/micafungin
  89. Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother 2016; 71:3599–3606 [View Article] [PubMed]
     [Google Scholar]
  90. Aldejohann AM, Wiese-Posselt M, Gastmeier P, Kurzai O. Expert recommendations for prevention and management of Candida auris transmission. Mycoses 2022; 65:590–598 [View Article] [PubMed]
     [Google Scholar]
  91. Szekely A, Borman AM, Johnson EM. Candida auris Isolates of the southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J Clin Microbiol 2019; 57:e02055-18 [View Article] [PubMed]
     [Google Scholar]
  92. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant 2017; 17:296–299 [View Article] [PubMed]
     [Google Scholar]
  93. Dang T, Bassett J, Souri A, Nutt A, Honza H et al. Transmission of pan-resistant and echinocandin-resistant Candida auris between healthcare facilities during the COVID-19 pandemic. Am J Infect Control 2022; 50:S2–S3 [View Article]
     [Google Scholar]
  94. Lockhart SR, Berkow EL, Chow N, Welsh RM. Candida auris for the clinical microbiology laboratory: not your Grandfather’s Candida species. Clin Microbiol Newslett 2017; 39:99–103 [View Article]
     [Google Scholar]
  95. Gupta AK, Venkataraman M. Antifungal resistance in superficial mycoses. J Dermatolog Treat 2022; 33:1888–1895 [View Article] [PubMed]
     [Google Scholar]
  96. Codda G, Willison E, Magnasco L, Morici P, Giacobbe DR et al. In vivo evolution to echinocandin resistance and increasing clonal heterogeneity in Candida auris during a difficult-to-control hospital outbreak, Italy, 2019 to 2022. Euro Surveill 2023; 28:2300161 [View Article] [PubMed]
     [Google Scholar]
  97. Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 2017; 23:162–164 [View Article] [PubMed]
     [Google Scholar]
  98. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 2014; 33:919–926 [View Article] [PubMed]
     [Google Scholar]
  99. Choi HI, An J, Hwang JJ, Moon SY, Son JS. Otomastoiditis caused by Candida auris: case report and literature review. Mycoses 2017; 60:488–492 [View Article] [PubMed]
     [Google Scholar]
  100. Chakrabarti A, Sood P. On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points. J Med Microbiol 2021; 70:001318 [View Article] [PubMed]
     [Google Scholar]
  101. Piatti G, Sartini M, Cusato C, Schito AM. Colonization by Candida auris in critically ill patients: role of cutaneous and rectal localization during an outbreak. J Hosp Infect 2022; 120:85–89 [View Article] [PubMed]
     [Google Scholar]
  102. Southwick K, Ostrowsky B, Greenko J, Adams E, Lutterloh E et al. A description of the first Candida auris-colonized individuals in New York State, 2016-2017. Am J Infect Control 2022; 50:358–360 [View Article] [PubMed]
     [Google Scholar]
  103. Patterson CA, Wyncoll D, Patel A, Ceesay Y, Newsholme W et al. Cloth lanyards as a source of intermittent transmission of Candida auris on an ICU. Crit Care Med 2021; 49:697–701 [View Article] [PubMed]
     [Google Scholar]
  104. Decker BK, Clancy CJ. Lanyards as source of a Candida auris outbreak: as you investigate the environment, do not overlook hand hygiene. Crit Care Med 2021; 49:714–716 [View Article] [PubMed]
     [Google Scholar]
  105. Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, Aleixandre-López AI, Martínez-Morel H et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses 2018; 61:498–505 [View Article] [PubMed]
     [Google Scholar]
  106. Schwartz IS, Smith SW, Dingle TC. Something wicked this way comes: what health care providers need to know about Candida Auris. Canada communicable disease report = Releve des maladies Transmissibles au Canada; 2018; 44271–276
  107. Krishnasamy L, Senthilganesh J, Saikumar C, Nithyanand P. Biofilm-forming fluconazole-resistant Candida auris causing vulvovaginal candidiasis in an immunocompetent patient: a case report. Asian Pac J Trop Med 2021; 14:94 [View Article]
     [Google Scholar]
  108. Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 2016; 1:e00189-16 [View Article] [PubMed]
     [Google Scholar]
  109. Forgács L, Borman AM, Prépost E, Tóth Z, Kardos G et al. Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model. Emerg Microbes Infect 2020; 9:1160–1169 [View Article] [PubMed]
     [Google Scholar]
  110. Fakhim H, Vaezi A, Dannaoui E, Chowdhary A, Nasiry D et al. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses 2018; 61:377–382 [View Article] [PubMed]
     [Google Scholar]
  111. Tian S, Bing J, Chu Y, Chen J, Cheng S et al. Genomic epidemiology of Candida auris in a general hospital in Shenyang, China: a three-year surveillance study. Emerg Microbes Infect 2021; 10:1088–1096 [View Article] [PubMed]
     [Google Scholar]
  112. Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S et al. Candida auris in Healthcare facilities; 2013; 24
  113. Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. Pharmacodynamic optimization for treatment of invasive Candida auris infection. Antimicrob Agents Chemother 2017; 61:e00791-17 [View Article] [PubMed]
     [Google Scholar]
  114. CDC Treatment and management of infections and colonization: centers for disease prevention and control 2021. n.d https://www.cdc.gov/fungal/candida-auris/c-auris-treatment.html
  115. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V et al. Development of high-level echinocandin resistance in a patient with recurrent Candida auris Candidemia secondary to chronic Candiduria. Open Forum Infect Dis 2019; 6:ofz262 [View Article] [PubMed]
     [Google Scholar]
  116. CDC. Clinical alert to U.S Healthcare facilities: centers for disease prevention and control; 2016 https://www.cdc.gov/fungal/candida-auris/candida-auris-alert.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fdiseases%2Fcandidiasis%2Fcandida-auris-alert.html
  117. O’Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe 2020; 1:e193–e194 [View Article] [PubMed]
     [Google Scholar]
  118. Balla N, Kovács F, Balázs B, Borman AM, Bozó A et al. Synergistic interaction of caspofungin combined with posaconazole against FKS wild-type and mutant Candida auris planktonic cells and biofilms. Antibiotics 2022; 11:1601 [View Article] [PubMed]
     [Google Scholar]
  119. John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP et al. Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris In Vitro. Antimicrob Agents Chemother 2023; 67:e0164522 [View Article] [PubMed]
     [Google Scholar]
  120. Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F et al. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother 2019; 74:3505–3510 [View Article] [PubMed]
     [Google Scholar]
  121. Ham YY, Lewis JS, Thompson GR. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol 2021; 16:27–36 [View Article] [PubMed]
     [Google Scholar]
  122. Pfaller MA, Huband MD, Rhomberg PR, Bien PA, Castanheira M. Activities of manogepix and comparators against 1,435 recent fungal isolates collected during an International Surveillance Program (2020). Antimicrob Agents Chemother 2022; 66:e0102822 [View Article] [PubMed]
     [Google Scholar]
  123. Vazquez JA, Pappas PG, Boffard K, Paruk F, Bien PA et al. Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with Candidemia caused by Candida auris: results from a phase 2 trial. Antimicrob Agents Chemother 2023; 67:e0141922 [View Article] [PubMed]
     [Google Scholar]
  124. Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob Agents Chemother 2017; 61: [View Article]
     [Google Scholar]
  125. Jaggavarapu S, Burd EM, Weiss DS. Micafungin and amphotericin B synergy against Candida auris. Lancet Microbe 2020; 1:e314–e315 [View Article] [PubMed]
     [Google Scholar]
  126. Escandón P, Chow NA, Caceres DH, Gade L, Berkow EL et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis 2019; 68:15–21 [View Article] [PubMed]
     [Google Scholar]
  127. Pacilli M, Kerins JL, Clegg WJ, Walblay KA, Adil H et al. Regional emergence of Candida auris in Chicago and lessons learned from intensive follow-up at 1 ventilator-capable skilled nursing facility. Clin Infect Dis 2020; 71:e718–e725 [View Article] [PubMed]
     [Google Scholar]
  128. Kenters N, Kiernan M, Chowdhary A, Denning DW, Pemán J et al. Control of Candida auris in healthcare institutions: outcome of an International Society for antimicrobial chemotherapy expert meeting. Int J Antimicrob Agents 2019; 54:400–406 [View Article] [PubMed]
     [Google Scholar]
  129. ECDC Candida auris in healthcare settings: European Centre for Disease Prevention and Control; 2016 https://www.ecdc.europa.eu/en/publications-data/candida-auris-healthcare-settings
  130. COTHI Interim guidance for management of Candida auris infections in South African hospitals: centre for opportunistic, tropical and hospital infections; 2016 https://www.nicd.ac.za/assets/files/2016-12-22%20InterimNICDRecommdtnsCAuris.pdf
  131. Govender NP, Avenant T, Brink A, Chibabhai V, Cleghorn J et al. Federation of Infectious Diseases Societies of Southern Africa guideline: recommendations for the detection, management and prevention of healthcare-associated Candida auris colonisation and disease in South Africa. S Afr J Infect Dis 2019; 34:163 [View Article] [PubMed]
     [Google Scholar]
  132. Ontario Agency for Health Protection and Promotion (Public Health Ontario) Provincial infectious diseases advisory committee interim guide for infection prevention and control of Candida auris; 2019 https://www.publichealthontario.ca/en/About/External-Advisory-Committees/PIDAC-IPC
  133. Vuichard-Gysin D, Sommerstein R, Martischang R, Harbarth S, Kuster SP et al. Candida auris - recommendations on infection prevention and control measures in Switzerland. Swiss Med Wkly 2020; 150:w20297 [View Article] [PubMed]
     [Google Scholar]
  134. Ong CW, Chen SC-A, Clark JE, Halliday CL, Kidd SE et al. Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. Intern Med J 2019; 49:1229–1243 [View Article] [PubMed]
     [Google Scholar]
  135. CDC Infection prevention and control for Candida auris: centers for disease prevention and control 2021. n.d https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html accessed 16 November 2021
  136. Caceres DH, Forsberg K, Welsh RM, Sexton DJ, Lockhart SR et al. Candida auris: a review of recommendations for detection and control in healthcare settings. J Fungi 2019; 5:111 [View Article] [PubMed]
     [Google Scholar]
  137. Alshamrani MM, El-Saed A, Mohammed A, Alghoribi MF, Al Johani SM et al. Management of Candida auris outbreak in a tertiary-care setting in Saudi Arabia. Infect Control Hosp Epidemiol 2021; 42:149–155 [View Article] [PubMed]
     [Google Scholar]
  138. Černáková L, Roudbary M, Brás S, Tafaj S, Rodrigues CF. Candida auris: a quick review on identification, current treatments, and challenges. Int J Mol Sci 2021; 22:4470 [View Article] [PubMed]
     [Google Scholar]
  139. Keri VC, Kumar A, Singh G, Xess I, Khan MA et al. Fungal carriage on healthcare workers’ hands, clothing, stethoscopes and electronic devices during routine patient care: a study from a tertiary care center. J Prev Med Hyg 2021; 62:E170–E173 [View Article] [PubMed]
     [Google Scholar]
  140. Bergeron G, Bloch D, Murray K, Kratz M, Parton H et al. Candida auris colonization after discharge to a community setting: New York City, 2017-2019. Open Forum Infect Dis 2021; 8:faa620 [View Article] [PubMed]
     [Google Scholar]
  141. Chaabane F, Graf A, Jequier L, Coste AT. Review on antifungal resistance mechanisms in the emerging pathogen Candida auris. Front Microbiol 2019; 10:2788 [View Article] [PubMed]
     [Google Scholar]
  142. Ku TSN, Walraven CJ, Lee SA. Candida auris: disinfectants and implications for infection control. Front Microbiol 2018; 9:726 [View Article] [PubMed]
     [Google Scholar]
  143. Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS. Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. J Hosp Infect 2017; 97:371–375 [View Article] [PubMed]
     [Google Scholar]
  144. Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses 2017; 60:758–763 [View Article] [PubMed]
     [Google Scholar]
  145. Kean R, Sherry L, Townsend E, McKloud E, Short B et al. Surface disinfection challenges for Candida auris: an in-vitro study. J Hosp Infect 2018; 98:433–436 [View Article] [PubMed]
     [Google Scholar]
  146. Ledwoch K, Maillard JY. Candida auris dry surface biofilm (DSB) for disinfectant efficacy testing. Materials 2018; 12:18 [View Article] [PubMed]
     [Google Scholar]
  147. Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL et al. Effectiveness of disinfectants against Candida auris and other Candida species. Infect Control Hosp Epidemiol 2017; 38:1240–1243 [View Article] [PubMed]
     [Google Scholar]
  148. de Groot T, Chowdhary A, Meis JF, Voss A. Killing of Candida auris by UV-C: importance of exposure time and distance. Mycoses 2019; 62:408–412 [View Article] [PubMed]
     [Google Scholar]
  149. Janniger EJ, Kapila R. Public health issues with Candida auris in COVID-19 patients. World Med Health Policy 2021; 13:766–772 [View Article] [PubMed]
     [Google Scholar]
  150. Zatorska B, Moser D, Diab-Elschahawi M, Ebner J, Lusignani LS et al. The effectiveness of surface disinfectants and a micellic H2O2 based water disinfectant on Candida auris. J Med Mycol 2021; 31:101178 [View Article]
     [Google Scholar]
  151. Cadnum JL, Pearlmutter BS, Haq MF, Jencson AL, Donskey CJ. Effectiveness and real-world materials compatibility of a novel hydrogen peroxide disinfectant cleaner. Am J Infect Control 2021; 49:1572–1574 [View Article] [PubMed]
     [Google Scholar]
  152. Pearlmutter BS, Haq MF, Cadnum JL, Jencson AL, Carlisle M et al. Efficacy of relatively low-cost ultraviolet-C light devices against Candida auris. Infect Control Hosp Epidemiol 2022; 43:747–751 [View Article] [PubMed]
     [Google Scholar]
  153. Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE, Weber DJ. Inactivation of Candida auris and Candida albicans by ultraviolet-C. Infect Control Hosp Epidemiol 2022; 43:1495–1497 [View Article]
     [Google Scholar]
  154. Fu L, Le T, Liu Z, Wang L, Guo H et al. Different efficacies of common disinfection methods against Candida auris and other Candida species. J Infect Public Health 2020; 13:730–736 [View Article] [PubMed]
     [Google Scholar]
  155. Astrid F, Beata Z, Van den Nest M, Julia E, Elisabeth P et al. The use of a UV-C disinfection robot in the routine cleaning process: a field study in an Academic hospital. Antimicrob Resist Infect Control 2021; 10:84 [View Article] [PubMed]
     [Google Scholar]
  156. Chatterjee P, Choi H, Ochoa B, Garmon G, Coppin JD et al. Clade-specific variation in susceptibility of Candida auris to broad-spectrum ultraviolet C light (UV-C). Infect Control Hosp Epidemiol 2020; 41:1384–1387 [View Article] [PubMed]
     [Google Scholar]
  157. Kurt AF, Kuskucu MA, Balkan IiI, Baris A, Yazgan Z et al. Candida auris fungemia and a local spread taken under control with infection control measures: first report from Turkey. Indian J Med Microbiol 2021; 39:228–230 [View Article] [PubMed]
     [Google Scholar]
  158. Lamont-Friedrich SJ, Kidd SE, Giles C, Griesser HJ, Coad BR. Candida auris susceptibility on surfaces coated with the antifungal drug caspofungin. Med Mycol Open Access 2021; 60: [View Article]
     [Google Scholar]
  159. Babiker A, Lutgring JD, Fridkin S, Hayden MK. Assessing the potential for unintended microbial consequences of routine chlorhexidine bathing for prevention of healthcare-associated infections. Clin Infect Dis 2021; 72:891–898 [View Article] [PubMed]
     [Google Scholar]
  160. Sherry L, Ramage G, Kean R, Borman A, Johnson EM et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis 2017; 23:328–331 [View Article] [PubMed]
     [Google Scholar]
  161. Proctor DM, Dangana T, Sexton DJ, Fukuda C, Yelin RD et al. Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility. Nat Med 2021; 27:1401–1409 [View Article] [PubMed]
     [Google Scholar]
  162. Huang X, Hurabielle C, Drummond RA, Bouladoux N, Desai JV et al. Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies. Cell Host Microbe 2021; 29:210–221 [View Article] [PubMed]
     [Google Scholar]
  163. Ghannoum M, Herrada J, McCormick TS, Long L. A novel transdermal application for clearing skin colonization by Candida auris. Antimicrob Agents Chemother 2023; 95:e02303-20 [View Article] [PubMed]
     [Google Scholar]
  164. Gavilanes-Martínez MA, Coral-Garzón A, Cáceres DH, García AM. Antifungal activity of boric acid, triclosan and zinc oxide against different clinically relevant Candida species. Mycoses 2021; 64:1045–1052 [View Article] [PubMed]
     [Google Scholar]
  165. Reimer-McAtee M, Corsi G, Reed E, Boston KM, Yalamanchili H et al. Successful implementation of the CDC recommendations during the care of 2 patients with Candida auris in in-patient rehabilitation and intensive care settings. Am J Infect Control 2021; 49:525–527 [View Article] [PubMed]
     [Google Scholar]
  166. Mohammed A, Alshamrani MM, El-Saed A, Cabanalan H, Alghoribi M et al. Management of Candida auris exposure among patients and healthcare workers at tertiary care setting. Antimicrob Resist Infect Control 2019; 8:
     [Google Scholar]
  167. ElBaradei A. A decade after the emergence of Candida auris: what do we know?. Eur J Clin Microbiol Infect Dis 2020; 39:1617–1627 [View Article] [PubMed]
     [Google Scholar]
  168. Borman AM, Johnson EM. Name changes for fungi of medical importance, 2018 to 2019. J Clin Microbiol 2021; 59:e01811-20 [View Article] [PubMed]
     [Google Scholar]
  169. Kim T-H, Kweon OJ, Kim HR, Lee M-K. Identification of uncommon Candida species using commercial identification systems. J Microbiol Biotechnol 2016; 26:2206–2213 [View Article] [PubMed]
     [Google Scholar]
  170. Dudiuk C, Berrio I, Leonardelli F, Morales-Lopez S, Theill L et al. Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris. J Antimicrob Chemother 2019; 74:2295–2302 [View Article] [PubMed]
     [Google Scholar]
  171. Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI et al. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev Iberoam Micol 2017; 34:23–27 [View Article] [PubMed]
     [Google Scholar]
  172. Snayd M, Dias F, Ryan RW, Clout D, Banach DB. Misidentification of Candida auris by RapID yeast plus, a commercial, biochemical enzyme-based manual rapid identification system. J Clin Microbiol 2018; 56:e00080-18 [View Article] [PubMed]
     [Google Scholar]
  173. Iguchi S, Itakura Y, Yoshida A, Kamada K, Mizushima R et al. Candida auris: a pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. J Infect Chemother 2019; 25:743–749 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001820
Loading
The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England
J. Med. Microbiol. 73, 001820 (2024); https://doi.org/10.1099/jmm.0.001820
/content/journal/jmm/10.1099/jmm.0.001820
/content/journal/jmm/10.1099/jmm.0.001820
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error